$REGN · REGENERON PHARMACEUTICALS, INC.
Regeneron filed an 8-K disclosing a Sixth Amendment to its Antibody License and Collaboration Agreement with Sanofi, adding four long-acting antibodies (IL-13, IL-4, IL-4Rα, IL-4xIL-13 bispecific) to the partnership. Sanofi will pay $1.0 billion upfront with up to $7.0 billion in additional milestone payments; global profits split 50/50. Separately, Regeneron expects a ~$22 million acquired IPR&D charge in Q3 2026 (~$0.18 per diluted share impact). The parties also settled Regeneron's lawsuit over Dupixent commercialization information access.
- Sanofi will pay Regeneron a $1.0 billion upfront payment under the Sixth Amendment to the Antibody LCA.
- The deal covers four long-acting Regeneron-invented antibodies targeting IL-13, IL-4, IL-4Rα, and a bispecific IL-4xIL-13.
- Regeneron can receive up to an additional $7.0 billion in development, regulatory, and commercial milestone payments.
- Global profits on the New Licensed Products will be shared equally (50/50) between Regeneron and Sanofi.
- Regeneron expects a ~$22M acquired IPR&D charge in Q3 2026, reducing GAAP and non-GAAP EPS by ~$0.18.
Markets closed — no regular-session reaction yet. Extended-hours last trade at $726.99 (+0.07% vs regular close), suggesting a muted initial response to the Sanofi deal expansion and the modest $0.18 IPR&D charge.
The deal extends one of biotech's most lucrative partnerships into next-generation IL-4/IL-13 pathway antibodies with $8B in total potential payments, while settling litigation that threatened the Dup
The deal deepens the Regeneron-Sanofi alliance that produced Dupixent, now targeting next-gen long-acting antibodies in the same IL-4/IL-13 pathway — a direct competitive moat play in immunology and inflammation.
Development costs exceeding the budget cap for New Licensed Products fall entirely on Regeneron, subject to limited recoupment rights. The Q3 2026 IPR&D charge is preliminary and unaudited; final results may differ.
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.